|
 |
DeferoxamineThis page contains recent news articles, when available, and an overview of Deferoxamine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Although the patients were asymptomatic, no further diagnostics such as bone biopsy, deferoxamine stimulation, or advanced cognitive tests were performed on RedOrbit, Global Epidemiology of Haemoglobin Disorders and Derived Service ... - Jun 14, 2008 Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-93. PMID:15477202 17. RedOrbit, New treatment boosts bone healing and regrowth - 02 Jun 2008 The researchers injected the drug deferoxamine (DF), which is designed to reduce iron overload, into injured mouse bones. They found DF triggered the growth TechJournal South, New Formulation Of Medication For Rare Disease Patients - May 7, 2008 The traditional first-line treatment for thalassaemia-related iron overload is deferoxamine, but patients find the treatment difficult, since it involves Medical News Today (press release), Cardiopulmonary Bypass: Principles and Practice - May 13, 2008 ...neutrophil depletion, erythropoietin, N-acetylcysteine, deferoxamine, and statins. This chapter was well constructed and practical in its approach. Journal of American Medical Association (subscription), Combined chelation an option for thalassemia-related myocardial ... - Mar 26, 2008 Combined chelation therapy with subcutaneous deferoxamine and oral deferiprone is effective in removing myocardial iron and improving cardiac function in Medicexchange, Strides Made in Red Blood Cell Disorders, but Substantial Barriers ... - Jan 29, 2008 This extension trial of 185 patients was a follow-up study to a 1-year trial that showed that deferasirox and deferoxamine were equally effective at Journal of American Medical Association (subscription), Formula for long life - Jan 15, 2008 The researchers injected the drug deferoxamine into injured mouse bones. The drug triggered the growth of new blood vessels, which in turn kicked off bone Chicago Tribune, Drug helps re-grow injured bone - Jan 11, 2008 In a study published online, in advance of the print edition of the journal Proceedings of the National Academy of Sciences, researchers said deferoxamine United Press International New Treatment Boosts Bone Healing And Regrowth - Jan 11, 2008 The researchers injected the drug deferoxamine (DF), which is designed to reduce iron overload, into injured mouse bones. They found DF triggered the growth Science Daily (press release) Sequential Deferiprone-Deferoxamine Tops Deferiprone Alone in ... - Dec 13, 2007 By Sophie Bainbridge ATLANTA, GA -- December 13, 2007 -- Sequential treatment with deferiprone plus deferoxamine is more effective than deferiprone alone DG News Adding Deferiprone to Deferoxamine Decreases Beta Thalassemia ... - Dec 13, 2007 The combination was individually tailored and included 40 to 60 mg/kg deferoxamine given by infusion 3 to 6 days/week and 75 to 100 mg/kg/day oral DG News The Labeling for Exjade (deferasirox) has Been Changed to Include ... - Dec 13, 2007 Nonprogressive increases in serum creatinine have been noted in 38% of EXJADE-treated patients, compared to 14% of deferoxamine-treated patients, PharmaLive.com (press release), Research Identifies Need for Improved Understanding of Sickle Cell ... - Dec 8, 2007 This trial evaluated deferiprone monotherapy compared with sequential treatment with deferiprone for four days followed by deferoxamine for three days. PR Newswire (press release), Deferasirox Retains Long-Term Efficacy in Iron Overload: Presented ... - Dec 10, 2007 Fifty-three of the patients had received deferoxamine, an infusion drug traditionally used for iron overload, in the randomized study and accepted DG News HIF stabilizing agents: shotgun or scalpel? - Aug 29, 2007 Toxic effects associated with the administration of deferoxamine in the premature baboon with hyaline membrane disease. Am J Dis Child 144: 915–919, 1990. AJP-Lung Physiology (subscription) Press Conference - Cyprus - Iron Overload - Jul 31, 2007 Canada NewsWire (press release),Over 30 years ago, an injectable iron chelator, deferoxamine, began to be administered to most patients in Cyprus, resulting in a prolongation of life. Bedford Laboratories to Begin Shipping Deferoxamine - Jun 19, 2007 PharmaLive.com (press release),Deferoxamine is an iron chelating agent indicated for the treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent Deferasirox Useful for Beta-Thalassaemia Patients With High Iron ... - Jun 11, 2007 DG NewsAll participants had been unsuccessfully treated with prior monotherapy or combination chelation therapy with deferoxamine and/or deferiprone, FDA - MedWatch - Exjade (deferasorix) Tablets For Oral Suspension ... - May 22, 2007 PharmaLive.com (press release),Nonprogressive increases in serum creatinine have been noted in 38% of Exjade-treated patients, compared to 14% of deferoxamine-treated patients, Data Presented At The International Symposium On Myelodysplastic ... - May 18, 2007 Medical News Today (press release),There are some drugs which can help chelate, or bind to iron to help remove it from the body, such as deferoxamine and deferasirox, and can reduce the FTC Challenges Hospira/Mayne Pharma Deal - 18 Jan 2007 PharmaLive.com (press release),Deferoxamine Mesylate. Injectable deferoxamine is an iron chelator used to treat acute iron poisoning or chronic iron overload. : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |